# MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

> **NCT02400814** · PHASE1 · TERMINATED · sponsor: **Megan Daly, MD** · enrollment: 27 (actual)

## Conditions studied

- Recurrent Non-Small Cell Lung Carcinoma
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Anti-PD-L1 Monoclonal Antibody MPDL3280A
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT02400814
- **Lead sponsor:** Megan Daly, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-03
- **Primary completion:** 2021-09-29
- **Final completion:** 2021-09-29
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Enrollment halted due to slow accrual.
- **Last updated:** 2022-08-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02400814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02400814, "MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02400814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*